490 related articles for article (PubMed ID: 31174610)
1. Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide.
Lee C; Jeong H; Bae Y; Shin K; Kang S; Kim H; Oh J; Bae H
J Immunother Cancer; 2019 Jun; 7(1):147. PubMed ID: 31174610
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Effect of Melittin-dKLA Targeting Tumor-Associated Macrophages in Melanoma.
Han IH; Jeong C; Yang J; Park SH; Hwang DS; Bae H
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328518
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Therapeutic Effect of Optimized Melittin-dKLA, a Peptide Agent Targeting M2-like Tumor-Associated Macrophages in Triple-Negative Breast Cancer.
Kim S; Choi I; Han IH; Bae H
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555393
[TBL] [Abstract][Full Text] [Related]
4. TAMpepK Suppresses Metastasis through the Elimination of M2-Like Tumor-Associated Macrophages in Triple-Negative Breast Cancer.
Lee C; Kim S; Jeong C; Cho I; Jo J; Han IH; Bae H
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216272
[TBL] [Abstract][Full Text] [Related]
5. Melittin suppresses tumor progression by regulating tumor-associated macrophages in a Lewis lung carcinoma mouse model.
Lee C; Bae SS; Joo H; Bae H
Oncotarget; 2017 Aug; 8(33):54951-54965. PubMed ID: 28903394
[TBL] [Abstract][Full Text] [Related]
6. Melittin derived peptide-drug conjugate, M-DM1, inhibits tumor progression and induces effector cell infiltration in melanoma by targeting M2 tumor-associated macrophages.
Jeong C; Kim J; Han IH; Kim S; Choi I; Kim H; Jeong JH; Bae H
Front Immunol; 2023; 14():1178776. PubMed ID: 37122692
[TBL] [Abstract][Full Text] [Related]
7. Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival.
Cieslewicz M; Tang J; Yu JL; Cao H; Zavaljevski M; Motoyama K; Lieber A; Raines EW; Pun SH
Proc Natl Acad Sci U S A; 2013 Oct; 110(40):15919-24. PubMed ID: 24046373
[TBL] [Abstract][Full Text] [Related]
8. Targeting Pro-Tumoral Macrophages in Early Primary and Metastatic Breast Tumors with the CD206-Binding mUNO Peptide.
Lepland A; Asciutto EK; Malfanti A; Simón-Gracia L; Sidorenko V; Vicent MJ; Teesalu T; Scodeller P
Mol Pharm; 2020 Jul; 17(7):2518-2531. PubMed ID: 32421341
[TBL] [Abstract][Full Text] [Related]
9. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
10. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages.
Qian Y; Qiao S; Dai Y; Xu G; Dai B; Lu L; Yu X; Luo Q; Zhang Z
ACS Nano; 2017 Sep; 11(9):9536-9549. PubMed ID: 28858473
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of multivalent M2pep peptides for targeting alternatively activated M2 macrophages.
Ngambenjawong C; Cieslewicz M; Schellinger JG; Pun SH
J Control Release; 2016 Feb; 224():103-111. PubMed ID: 26772876
[TBL] [Abstract][Full Text] [Related]
12. Modulation the crosstalk between tumor-associated macrophages and non-small cell lung cancer to inhibit tumor migration and invasion by ginsenoside Rh2.
Li H; Huang N; Zhu W; Wu J; Yang X; Teng W; Tian J; Fang Z; Luo Y; Chen M; Li Y
BMC Cancer; 2018 May; 18(1):579. PubMed ID: 29783929
[TBL] [Abstract][Full Text] [Related]
13. Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy.
Cao Y; Qiao B; Chen Q; Xie Z; Dou X; Xu L; Ran H; Zhang L; Wang Z
Acta Biomater; 2023 Apr; 160():239-251. PubMed ID: 36774974
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib inhibits M2-like polarization of tumor-associated macrophages in Lewis lung cancer by targeting the STAT6 signaling pathway.
Tariq M; Zhang JQ; Liang GK; He QJ; Ding L; Yang B
Acta Pharmacol Sin; 2017 Nov; 38(11):1501-1511. PubMed ID: 29022575
[TBL] [Abstract][Full Text] [Related]
15. Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel.
Dai X; Meng J; Deng S; Zhang L; Wan C; Lu L; Huang J; Hu Y; Zhang Z; Li Y; Lovell JF; Wu G; Yang K; Jin H
Theranostics; 2020; 10(7):3049-3063. PubMed ID: 32194854
[TBL] [Abstract][Full Text] [Related]
16. Lactoferrin-containing immunocomplex mediates antitumor effects by resetting tumor-associated macrophages to M1 phenotype.
Dong H; Yang Y; Gao C; Sun H; Wang H; Hong C; Wang J; Gong F; Gao X
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217759
[TBL] [Abstract][Full Text] [Related]
17. Selective targeting of tumor associated macrophages in different tumor models.
Kakoschky B; Pleli T; Schmithals C; Zeuzem S; Brüne B; Vogl TJ; Korf HW; Weigert A; Piiper A
PLoS One; 2018; 13(2):e0193015. PubMed ID: 29447241
[TBL] [Abstract][Full Text] [Related]
18. Targeting tumor-associated macrophages in the tumor microenvironment.
Zhou K; Cheng T; Zhan J; Peng X; Zhang Y; Wen J; Chen X; Ying M
Oncol Lett; 2020 Nov; 20(5):234. PubMed ID: 32968456
[TBL] [Abstract][Full Text] [Related]
19. Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses.
Wang YC; He F; Feng F; Liu XW; Dong GY; Qin HY; Hu XB; Zheng MH; Liang L; Feng L; Liang YM; Han H
Cancer Res; 2010 Jun; 70(12):4840-9. PubMed ID: 20501839
[TBL] [Abstract][Full Text] [Related]
20. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
